Novel Vascular Treatment for Erectile Dysfunction

An estimated 350 million men suffer from erectile dysfunction. PDE5 inhibitors such as Viagra, which revolutionized this field, are only effective in 50% of the cases. The other 50% and their partners are left with little to no options. The alternatives are the often painful and ineffective selections of rubber bands, vacuum pumps, penile injection and when it comes to last resort, silicon prosthesis. Those options attempt to treat the symptoms but do not address the biological causes of ED. One of the leading causes of ED is incomplete inhibition of venous outflow during erection, an issue that was never properly addressed and for which there is no device approved anywhere in the world.

PDE5 inhibitors address the arterial side of ED by increasing blood inflow, but no one addresses the complex drainage issue. Therefore, we have developed a minimally invasive vascular outpatient treatment for ED. The treatment consists of a micro implant that restores the biological Veno-Occlusion mechanism of the body. This mechanism maintains the necessary blood flow in the flaccid state and inhibits blood flow during the erect state. Our first patients are non-responders to PDE5i and after years without normal function, they finally have hope with promising initial results. Our clinical studies are ongoing with clinical sites in Israel and New Zealand to be followed by US sites. We expect our product will create a new treatment paradigm that will benefit millions of men and their partners.

Sano V was founded by the Singapore MedTech Accelerator with financial support from the Singapore government. It is graduating from the accelerator and is looking for its first external funding. The product was invented by the team that invented The AngioSculpt scoring balloon (now with Philips) and the Chocolate Balloon which is now owned by Medtronic (peripheral) and Teleflex (coronary). We are Sano V, and we are restoring vitality.